Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262738 · ClinicalTrials.gov registry record · Phase 4
Misoprostol Dosing in BMI Greater Than 30
A Phase 4 study of Obesity and Pregnancy Related, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT05262738 is a Phase 4 study of Obesity and Pregnancy Related that has completed, run by University of Texas at Austin. The registered enrollment target is 180 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05262738, a Phase 4 study of Obesity and Pregnancy Related, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.
Conditions Studied
Interventions
- DRUG 50 Micrograms Vaginal Misoprostol (Intervention)
- DRUG 25 Micrograms Vaginal Misoprostol (Control)
Study Locations (1)
Texas
- University of Texas at Austin Dell Medical School, Department of Women's Health - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-07-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262738
The ClinicalTrials.gov registry entry for NCT05262738 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which 50 Micrograms Vaginal Misoprostol (Intervention) is the first listed.
NCT05262738 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05262738 about?
NCT05262738 is a clinical study titled "Misoprostol Dosing in BMI Greater Than 30". The investigators are performing a randomized controlled-trial investigating if 50mcg (compared to 25 mcg) of vaginal misoprostol reduces the time from induction start to delivery in obese women.
What is the current status of trial NCT05262738?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2022-06-01. Estimated completion is 2023-07-17.
What conditions does trial NCT05262738 study?
This clinical trial studies the following conditions: Obesity, Pregnancy Related, Labor Onset and Length Abnormalities.
What interventions are being tested in trial NCT05262738?
The interventions under investigation include: 50 Micrograms Vaginal Misoprostol (Intervention) (DRUG), 25 Micrograms Vaginal Misoprostol (Control) (DRUG).
Who is sponsoring clinical trial NCT05262738?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05262738 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.